Clinical Trial Update: Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial evaluating cord blood-derived NK cells engineered with NY-ESO-1 TCR/IL-15 for relapsed/refractory multiple myeloma is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Cord blood-derived NK cells engineered with NY-ESO-1 TCR/IL-15 receptor (engineered natural killer cell therapy targeting NY-ESO-1 with IL-15 receptor)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloma | Phase 1, Phase 2 | Status: RECRUITING